(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 10.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Mannkind's revenue in 2026 is $393,630,000.On average, 10 Wall Street analysts forecast MNKD's revenue for 2026 to be $145,439,260,928, with the lowest MNKD revenue forecast at $134,593,695,242, and the highest MNKD revenue forecast at $155,034,033,536. On average, 10 Wall Street analysts forecast MNKD's revenue for 2027 to be $165,297,610,669, with the lowest MNKD revenue forecast at $139,828,376,812, and the highest MNKD revenue forecast at $189,065,894,556.
In 2028, MNKD is forecast to generate $169,664,132,519 in revenue, with the lowest revenue forecast at $141,593,634,909 and the highest revenue forecast at $205,136,495,593.